NEW YORK, Sept. 20 – Merck's wholly owned subsidiary Rosetta Inpharmatics said Thursday it had established a new business unit, Rosetta Biosoftware, to develop and sell new bioinformatics software for life science research.

The new business unit, which will be based in Kirkland, Wash., will continue to develop new versions of Rosetta’s flagship product, the Rosetta Resolver Gene Expression Data Analysis System.

Agilent Technologies will remain the exclusive distributor of Rosetta software.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The New York Times reports that as China invests in science, it also is dealing with research fraud.

In PLOS this week: transcriptome study of a cold-tolerant plant, deep sequencing of clinical influenza A samples, and more.

The Atlantic writes that retrotransposons like BovB have proliferated in a number of genomes.

Researchers have sequenced the genome of a man who lived in China some 40,000 years ago, according to UPI.